Brief Description
Genocea finds targets of T cell responses to discover and develop life-changing medicines. The company created a pipeline of novel vaccine and immunotherapy programs that stimulate the T cell arm of the immune system, which is increasingly recognized as critical to generating protective immune responses against a wide array of diseases. Genocea designs its medicines using ATLASª, a proprietary technology platform. Genocea's platform has the potential to revolutionize vaccines and immunotherapies for a range of infectious diseases, cancers and autoimmune diseases. The company was co-founded by Darren Higgens based on discoveries while he was a postdoc in the lab of Daniel Portnoy, UC Berkeley professor of Biochemistry, Biophysics, and Structural Biology in the Department of Molecular and Cell Biology and the Department of Plant & Microbial Biology.
Timeline
- 2006. Company founded.
- 2014. Initial Public Offering on NASDAQ with the ticker symbol GNCA